VT6 Stock Overview
A biotechnology company, focuses on the treatment of gene therapy and neurology diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Voyager Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.20 |
| 52 Week High | US$10.10 |
| 52 Week Low | US$5.01 |
| Beta | 0.89 |
| 11 Month Change | -15.53% |
| 3 Month Change | -14.84% |
| 1 Year Change | -14.84% |
| 33 Year Change | 84.22% |
| 5 Year Change | -57.42% |
| Change since IPO | -71.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| VT6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.3% | -0.7% | 0.2% |
| 1Y | -14.8% | -17.2% | 8.5% |
Return vs Industry: VT6 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: VT6 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| VT6 volatility | |
|---|---|
| VT6 Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: VT6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: VT6's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 162 | Al Sandrock | www.voyagertherapeutics.com |
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer’s disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer’s disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer’s disease and is in preclinical trial.
Voyager Therapeutics, Inc. Fundamentals Summary
| VT6 fundamental statistics | |
|---|---|
| Market cap | €294.33m |
| Earnings (TTM) | €24.66m |
| Revenue (TTM) | €156.05m |
12.1x
P/E Ratio1.9x
P/S RatioIs VT6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VT6 income statement (TTM) | |
|---|---|
| Revenue | US$163.78m |
| Cost of Revenue | US$117.54m |
| Gross Profit | US$46.24m |
| Other Expenses | US$20.36m |
| Earnings | US$25.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 28.23% |
| Net Profit Margin | 15.80% |
| Debt/Equity Ratio | 0% |
How did VT6 perform over the long term?
See historical performance and comparison